Foundation Medicine, Inc.

Foundation Medicine is a precision oncology diagnostics company specializing in comprehensive genomic profiling (CGP) and companion diagnostic testing for advanced cancer patients. The company develops and commercializes FDA-approved next-generation sequencing (NGS) based in vitro diagnostic tests, including FoundationOne®CDx (tissue-based) and FoundationOne®Liquid CDx (blood-based, circulating cell-free DNA). FoundationOne CDx analyzes 324 genes plus genomic signatures from formalin-fixed, paraffin-embedded (FFPE) tissue samples. FoundationOne Liquid CDx analyzes 324 genes using plasma specimens, reporting short variants in 311 genes, rearrangements in 8 genes, and copy number alterations in 3 genes. Foundation Medicine also offers FoundationOne Heme testing and IHC (immunohistochemistry) services. The company serves three core markets: healthcare providers and oncologists seeking biomarker-driven treatment selection; biopharmaceutical and research partners requiring companion diagnostic development, clinical trial support, and regulatory expertise across the drug development lifecycle; and patients seeking personalized cancer treatment guidance. Foundation Medicine operates a global laboratory with comprehensive EMR integration capabilities and provides decision support services and educational resources to clinicians. The company has delivered over 1.5 million genomic profiling reports and holds more than 50% of all approved US companion diagnostic indications for NGS testing. Services span discovery and translational research, clinical development and CDx strategy, and access and commercialization support. The company is FDA-regulated and maintains rigorous quality standards for molecular diagnostics.